Common Respiratory Viruses Linked to Heart Events in the Short-Term: The University of Melbourne
By Business Wire India Published on June 25, 2025, 11:43 IST
New Delhi, Delhi, India:
Common viral respiratory infections such as COVID-19, Respiratory syncytial virus (RSV) and influenza are linked to an increased short-term risk of stroke and heart attack in adults, new University of Melbourne research has found.
Drawing on the best available evidence from 48 studies, researchers from the University of Melbourne and Murdoch Research Children's Institute (MCRI) led a comprehensive meta-analysis and systematic review to investigate common respiratory viruses and their role in cardiovascular events such as heart attacks and strokes.
'There is growing evidence these viruses can act as triggers for heart attacks and strokes, butto date there has been a focus on influenza,' Tu Nguyen, a PhD candidate in the Epidemiology-Informatics research group at Murdoch Children's Research Institute and the Department of Pediatrics, University of Melbourne, said. 'This study provides a better picture of the role of other respiratory viruses. '
'We focussed specifically on laboratory-confirmed infections and found that common respiratory viruses play a role in precipitating acute cardiovascular events, but how strong the link is varies between viruses.'
Heart attacks and stroke remain the leading causes of premature death globally.
The research, published today in the journal Cardiovascular Research , has potential implications for at-risk groups, particularly in cold and flu season.
'While it's true that heart attacks and strokes are an adult disease, respiratory infections mostly affect young children, which can spread to older adults in their community,' Ms Nguyen said.
'Older adults are more vulnerable to serious events like heart attacks or strokes that can arise from these infections so that's why studying this relationship helps us understand these risks at the community level, and may encourage older Australians to get immunised where they can as many are vaccine preventable.'
Professor Jim Buttery, Head of Epidemiology Informatics Research Group at MCRI and Professor of Child Health Informatics at the University of Melbourne, said the research is important for an ageing population, and to better inform public health strategies. 'This research provides us with more knowledge about why it's important for older Australians to prevent respiratory infections, where possible, given the potential risk factors,' he said. 'While this study brings together the most up-to-date information we have, we don't have all that much data for the Australian population, so our future research will look to fill this gap, so that we have a better picture of this link in the Australian context.'
The team, alongside collaborators in Western Australia and Queensland, plan to investigate and map the distribution of common infections for Australians using the power of a collaborative, ecological data platform called Snot Watch .
The platform was established in 2019 to better understand how virus levels relate to Victorians' health.
'With our colleagues in Western Australia and Queensland, we will now use real-world statewide data from all three states to understand these risks better and help inform vaccine and treatment decisions,' Professor Buttery said.
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
40-year-old reaches millions on TikTok as 'The Workout Witch': I found a 'deep sense of purpose'
To better understand the cause of her chronic pain and insomnia, Liz Tenuto majored in psychology. Her studies led her to psychotherapy for healing, like EMDR, and a better understanding of how the nervous system operates. While working as a professional dancer after college, a suggestion from her teacher put Tenuto on the path to becoming "The Workout Witch." "It was actually my ballet teacher who noticed that I was very dissociated when I wasn't dancing," Tenuto, 40, tells CNBC Make It. "[They] kind of nudged me to take a somatics class." In 2008, somatic exercises were still pretty new to most people. "For me, it just looked like a bunch of people rolling around in their pajamas on the floor," Tenuto says. "So I was very skeptical at first, especially with an academic background." Somatic exercises were created to relieve tension from the body and entail moving in slow and mindful ways that shift the focus from how you look to what you feel. Yoga, breathwork and dance are all considered forms of somatic movement. "It's micro-movements. They're really tiny, and you do very little in a class," Tenuto says. In the sessions she attended, "we maybe did three or four movements in an entire hour and a half class. And it had profound effects." Somatic movements can be beneficial for a number of reasons, but is most widely touted for its effect on the nervous system. "Our nervous system has different ways that it can be activated — sympathetic activation, which is fight-flight, and parasympathetic activation, which is freeze or shut down," she says. In between those two modes of activation is a middle ground called the "ventral vagal state," which is a state of homeostasis. "You're balanced, you're social, you're grounded, you're regulated," she explains. The polyvagal theory indicates that doing somatic exercises may put you in the ventral vagal state, lead to better emotional regulation and get you out of fight or flight. "You're just reinforcing safety in your body as you do them over and over again, and you're practicing this regulated state," Tenuto says. "It's similar to building muscle. As you continue to build those new neural pathways and practice the exercises, that starts to become stronger than some of your trauma responses." During the Covid-19 shutdown in 2020, Tenuto began uploading videos of herself demonstrating somatic exercises to the social media platform TikTok, which was gaining in popularity at the time. "I was posting the exercises, really to just hold me accountable for doing one exercise per day. Because at that time, I was having a really hard time just getting out of bed," she says. "I was very sad at the time. I was going through a divorce." Tenuto says sharing that daily exercise was the only thing that helped, and she was stunned when her account went from zero followers to 10,000 in just two to three weeks. Today, she's at 2.2 million. Before the pandemic, Tenuto taught Pilates and somatics classes and had private clients who she guided through injury recovery. Seeing how receptive the audience on TikTok and Instagram were to her videos filled her up with a "deep sense of purpose," she says, and showed that sharing her work online could be just as effective. Now, Tenuto's somatic therapy demonstrations for healing trauma, alleviating symptoms of anxiety and shifting out of "functional freeze" go viral. Tenuto deemed herself "The Workout Witch" because "when people experience these exercises, they do think that there's some magic, and some like woo woo stuff going on with them," she says. "I wish there was, but it's really just using neuroscience with movement."
Axios
an hour ago
- Axios
Building breakthroughs: Gilead invests in U.S. innovation
Gilead's $32B U.S. investment is fueling American science — and innovation. At Gilead, we strive to create a healthier world for all people. Gilead invests in world-class science and is pursuing innovation across the therapeutic areas of virology, oncology and inflammation. Gilead is investing $32 billion in the U.S. through 2030 to expand research, manufacturing and workforce infrastructure as part of a broader global strategy to deliver scientific breakthroughs where they can have the greatest impact. The idea: Biopharmaceutical innovation can't happen without infrastructure. Gilead's expansion strategy helps ensure transformative medicines are discovered and delivered at home — while reinforcing the global pipeline that supports patients around the world. "Our U.S. investment strategy reflects a simple belief: that the future of medicine should be built here," said Daniel O'Day, Chairman and CEO of Gilead Sciences. "By strengthening our American footprint as part of a global innovation engine, we're helping ensure patients everywhere benefit from our world-class therapies." The strategy: Gilead's U.S. investment includes: Investing in AI-enabled labs and advanced manufacturing sites. Creating over 3,000 direct and supported jobs. Expanding capacity for personalized therapies and large-scale production. These efforts are designed to speed access to innovation, build supply chain resilience and redefine what's possible in medicine. Key numbers: 98% of Gilead's R&D infrastructure is U.S.-based. 80%+ of profits are reinvested in the U.S. $43B in projected U.S. economic impact. Investing in our promise Since 2017, Gilead has added more than 16,000 high-quality U.S. jobs, with over 70% of domestic employees focused on R&D. New investments are fueling advanced treatments in virology, inflammation and cancer. At Gilead, every investment begins with people and ends with purpose. Our commitment to expanding U.S. infrastructure goes beyond facilities — it's about empowering communities and strengthening public health for the long term. Engineering a new era of American innovation The details: Gilead is harnessing AI and automation to transform how medicines are discovered, manufactured, and delivered — faster, smarter and more safely. Next-generation facilities in California will be equipped with predictive analytics, digital monitoring and autonomous robotics. Designed in collaboration with Bay Area tech startups, these facilities set a new standard for biopharma infrastructure and speed — from groundbreaking to completion in under two years. With more than $5 billion invested in facilities that map the flow of scientific innovation — from research to clinical manufacturing — Gilead's campuses embody the speed and agility of our discoveries. Building resilience through science Plus, plus, plus: During COVID-19, Gilead's U.S.-anchored supply chain ensured uninterrupted global access to essential treatments. With the majority of our workforce and intellectual property based in the U.S. — and a global footprint spanning 70 sites across 38 countries — they're building a system that can adapt, shift and scale in real time. Strategic redundancy, flexible manufacturing and proven partnerships make our network a cornerstone of health security. A global commitment, rooted at home Worth a mention: While expanding its U.S. footprint, Gilead continues to invest in research, manufacturing and partnerships abroad. A globally integrated model ensures patients everywhere benefit from discoveries made at home. Whether scaling a COVID-19 antiviral across continents or sourcing ingredients for personalized therapies, Gilead's global operations balance efficiency with equity — and keep patients at the center of everything they do.
an hour ago
Kennedy's new vaccine advisers meet for first time
ATLANTA -- U.S. Health Secretary Robert F. Kennedy Jr.'s new vaccine advisers began their first meeting Wednesday under intense scrutiny from medical experts worried about Americans' access to lifesaving shots. First on the agenda is an awkward scenario: Kennedy already announced COVID-19 vaccines will no longer be recommended for healthy children or pregnant women, and his new advisers aren't scheduled to vote on whether they agree. Yet government scientists prepared meeting materials calling vaccination 'the best protection' during pregnancy — and said most children hospitalized for COVID-19 over the past year were unvaccinated. COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months who could have some protection if their mom got vaccinated during pregnancy, according to the CDC's presentation. It's one signal that this week's two-day meeting of the Advisory Committee on Immunization Practices isn't business as usual. Another sign: Shortly before the meeting, a Virginia-based obstetrician and gynecologist stepped down from the committee, bringing the panel's number to just seven. The Trump administration said Dr. Michael Ross withdrew during a customary review of members' financial holdings. The meeting opened as the American Academy of Pediatrics announced that it will continue publishing its own vaccine schedule for children but now will do so independently of the ACIP, calling it 'no longer a credible process.' The panel, created more than 60 years ago, helps the CDC determine who should be vaccinated against a long list of diseases, and when. Those recommendations have a big impact on whether insurance covers vaccinations and where they're available, such as at pharmacies. Earlier this month, Kennedy abruptly dismissed the existing 17-member expert panel and handpicked eight replacements, including several anti-vaccine voices. And a number of the CDC's top vaccine scientists — including some who lead the reporting of data and the vetting of presentations at ACIP meetings — have resigned or been moved out of previous positions. The highly unusual moves prompted a last-minute plea from a prominent Republican senator to delay this week's meeting. Sen. Bill Cassidy of Louisiana, a physician who chairs the chamber's health committee, said Monday that many of Kennedy's chosen panelists lack the required expertise and 'may even have a preconceived bias' against new vaccine technologies. In a House hearing Tuesday, Kennedy defended his purge, saying the old panel had been 'a template for medical malpractice.' Rep. Kim Schrier, a pediatrician and Democrat from Washington state, told Kennedy: 'I will lay all responsibility for every death from a vaccine-preventable illness at your feet.' The two-day meeting's agenda on was abruptly changed last week. Discussion of COVID-19 shots will open the session on Wednesday. Later in the day, the committee will take up RSV, with votes expected. On Thursday, the committee will vote on fall flu vaccinations and on the use of a preservative in certain flu shots. RSV, or respiratory syncytial virus, is a common cause of cold-like symptoms that can be dangerous for infants. In 2023, U.S. health officials began recommending two new measures to protect infants — a lab-made antibody for newborns and a vaccine for pregnant women — that experts say likely drove an improvement in infant mortality. The committee will discuss another company's newly approved antibody shot, but the exact language for the vote was not released prior to the meeting. 'I think there may be a theme of soft-pedaling or withdrawing recommendations for healthy pregnant women and healthy children,' even though they are at risk from vaccine-preventable diseases, said Lawrence Gostin, a public health law expert at Georgetown University who co-authored a recent medical journal commentary criticizing the COVID-19 vaccination decision. At its June meetings, the committee usually refreshes guidance for Americans 6 month and older to get a flu shot, and helps greenlight the annual fall vaccination campaign. But given the recent changes to the committee and federal public health leadership, it's unclear how routine topics will be treated, said Jason Schwartz, a Yale University health policy researcher who has studied the committee. Thursday also promises controversy. The advisory panel is set to consider a preservative in a subset of flu shots that Kennedy and some antivaccine groups have falsely contended is tied to autism. In preparation, the CDC posted a new report confirming that research shows no link between the preservative, thimerosal, and autism or any other neurodevelopmental disorders. Gostin said the agenda appears to be 'a combination of what we would normally expect ACIP to cover along with a mixture of potential conspiracy theories,' he said. 'We clearly are in a new normal that's highly skeptical of vaccine science.' The committee's recommendations traditionally go to the Centers for Disease Control and Prevention director. Historically, nearly all are accepted and then used by insurance companies in deciding what vaccines to cover. But the CDC currently has no director, so the committee's recommendations have been going to Kennedy, and he has yet to act on a couple recommendations ACIP made in April. Neergaard reported from Washington. ___
